Loading stock data…
IMTX
$10.79-0.20 (-1.82%)
Market ClosedLast close May 1
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Immatics N.V. in the Healthcare sector is trading at $10.79. The stock is currently near its 52-week high of $12.41, remaining 19.0% above its 200-day moving average. Technical signals show neutral RSI of 48 and bearish MACD signal, explaining why IMTX maintains its current momentum and trend strength. The Whystock Score of 75/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Neutral momentum (RSI 48) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$10.79
Potential Upside
5%
Whystock Fair Value$11.33
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies wi...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.51B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.34
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-40.58%
Volume
Today's trading volume
206,566
Recent News
Immatics Phase 3 Progress Sharpens View On Anzu Cel Launch Upside
Immatics (NasdaqCM:IMTX) reported strong enrollment in its Phase 3 SUPRAME trial for anzu-cel (IMA203), its lead cancer immunotherapy candidate. The company has set timelines for the final analysis of the trial and is targeting a future product launch following completion. This update outlines the next key clinical and regulatory steps for Immatics' late stage oncology pipeline. Immatics focuses on T cell based cancer therapies, with anzu-cel at the center of its late stage efforts. For you...
Immatics N.V. (IMTX) Seeing Strong Enrollment in a Key Phase 3 Trial of Drug Candidate
Immatics N.V. (NASDAQ:IMTX) is among the best German stocks to buy according to analysts. On March 5, Immatics N.V. (NASDAQ:IMTX) reported its financial results for the year ended December 31. It also provided updates on its business. On the financial part, the company reported revenue of $56.8 million, compared to revenue of $183.1 million in […]
Immatics: Q4 Earnings Snapshot
TUBINGEN, Germany (AP) — Immatics N.V. (IMTX) on Thursday reported a loss of $41.6 million in its fourth quarter. The Tubingen, Germany-based company said it had a loss of 34 cents per share. The company posted revenue of $23 million in the period.
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q4 Loss, Tops Revenue Estimates
Mirum Pharmaceuticals (MIRM) delivered earnings and revenue surprises of -650.00% and +5.42%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Institutional investors own a significant stake of 38% in Immatics N.V. (NASDAQ:IMTX)
Key Insights Significantly high institutional ownership implies Immatics' stock price is sensitive to their trading...